Sequential Targeting Of Pi3k Delta And Lag3 As An Effective Anti-Cancer Approach

Emerging studies have demonstrated the potential of PI3K delta blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3K delta-based immunotherapy, enabling successful tumour control in all treated mice.